On December 20, 2024, InflaRx N.V. reported that the first patient was dosed in a study for its oral C5aR inhibitor, INF904, targeting chronic spontaneous urticaria and hidradenitis suppurativa. The Phase 2a study aims to include 75 patients over four weeks and generate data for future research.